Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database

Keyphrases

• Weight Loss 100%
• Multiple Sclerosis 100%
• Reporting Odds Ratio 100%
• Adverse Event Reporting System Database 100%
• FDA Adverse Event Reporting System (FAERS) 100%
• Inverse Association 50%
• Antidiabetic 25%
• Metformin 25%
• Repurposing 25%
• Liraglutide 25%
• Pro-inflammatory Adipokines 25%
• Empagliflozin 25%
• Semaglutide 25%
• Dulaglutide 25%
• Risk Factors 12%
• Confidence Interval 12%
• Adiponectin 12%
• U.S. Food 12%
• Obesity 12%
• Receptor Agonist 12%
• Glucagon-like 12%
• A1 Receptor 12%
• Amphetamine 12%
• Topiramate 12%
• Existing Drugs 12%
• Existing Data 12%
• Leptin 12%
• Adverse Drug Reaction 12%
• New Indication 12%
• Overproduction 12%
• Drug Safety 12%
• Bupropion 12%
• Drug Repurposing 12%
• Safety Signal 12%
• Naltrexone 12%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 12%
• Early Adolescents 12%
• Zonisamide 12%
• Biguanides 12%
• Early childhood Obesity 12%
• Disproportionality Analysis 12%
• Phentermine 12%
• Adolescent Obesity 12%
• Multiple Weights 12%
• Inverse Potential 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• FDA Adverse Event Reporting System 100%
• Adverse Event 57%
• Adipocytokine 28%
• Antidiabetic Agent 28%
• Metformin 28%
• Repurposing 28%
• Liraglutide 28%
• Empagliflozin 28%
• Semaglutide 28%
• Dulaglutide 28%
• Prospective Study 14%
• Childhood Obesity 14%
• Adiponectin 14%
• Leptin 14%
• Anti-Inflammatory Drug 14%
• Topiramate 14%
• Adverse Drug Reaction 14%
• Drug Repositioning 14%
• Glucagon Like Peptide 1 Receptor Agonist 14%
• Bupropion 14%
• Naltrexone 14%
• Sodium Glucose Cotransporter 2 Inhibitor 14%
• Zonisamide 14%
• Amphetamine 14%
• Disproportionality Analysis 14%
• Phentermine 14%
• Adolescent Obesity 14%
• Biguanide 14%